findmyKOL
Clinical trialNCT02269670TerminatedPhase 2Interventional

Phase II Study of Everolimus Beyond Progression

SponsorEmory UniversityEnrollment3Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Emory Saint Joseph'S Hospital

    Atlanta, Georgia, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, United States

  • Emory University/winship Cancer Institute

    Atlanta, Georgia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Nov 2014
Primary completion
25 Jan 2021
Completion
25 Jan 2021
Last update posted
5 Apr 2022
Registered enrollment
3
Registry id
NCT02269670

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.